Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Relationship between serum CA125 half life and survival in ovarian cancer

From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

First Author, Year, Study Place Data Collection Study Design Sample Size Groups being Compared RR/HR, (95% CI), P-Value Conclusion Variables Adjusted for
Riedinger JM, 2008, France [64] 1996 to 2000 Multicentric Retrospective study 130 Non-assessable, ≤ 14 days and mono-exponential decay, ≤ 14 days and bi-exponential decay, > 14 days NA The CA125 group classification was found to be an independent prognostic factor only for DFS CA125 nadir, chemotherapy courses, residual tumor
Riedinger JM, 2006, France [38] 1988 to 1996 Multicentric Retrospective study 553 ≤ 14 days, > 14 days 2.04 (1.58-2.63), < 0.0001 Among well-established prognostic factors in ovarian cancers, CA125 half-life and nadir concentration bear a strong and independent prognostic value FIGO stage, residual tumor, age, CA125 nadir
Gadducci A, 2004, Italy [65] 1996 to 2002 Retrospective study 71 ≤ 14 days, > 14 days 3.11 (1.22--7.98), 0.0181 Serum CA125 half-life was an independent prognostic factor for the chance of achieving a complete response to treatment as well as for progression-free survival and overall survival Age, Histology
FIGO stage, Residual disease, chemotherapy regimen, CA125 percentage reduction after the first cycle of chemotherapy
Colakovic S, 2000, Yugoslavia [51] NA Retrospective study 222 < 20 days, > 20 days NA, 0.007 CA125 half life can divide patients into good and poor prognostic groups early during chemotherapy Therapeutic response Karnofsky index, residual disease, tumor grade, CA125 kinetics
Munstedt K, 1997, Germany [63] 1987 to 1994 Retrospective study 85 < 20 days, > 20 days 0.6184 Serum CA125 half-life did not have any significant correlation with survival Age, FIGO stage, Histology, grades
Gadducci A, 1995, Italy [40] 1986 to 1992 Multicentric Retrospective study 225 < 25 days, ≥ 25 days 2.13 (1.23-3.68), 0.0073 Serum CA125 half-life during early chemotherapy was an independent prognostic factor for both achievement of a pathological complete response and survival FIGO stage, Tumor grade, size of residual disease, CA125 level
Rosman M, 1994, Connecticut [66] June 1985 to July 1989 Retrospective study 51 ≤ 12 days, > 12 days 3.6 (1.8-7.4), < 0.001 In those patients in whom residual small volume disease after primary surgery indicates a good prognosis, minimum CA125 and CA125 t1/2 during chemotherapy can further categorize patients into favourable and unfavourable prognostic groups FIGO stage, tumor grade, residual disease, CA125
Yedema C A, 1993, Netherlands [52] July 1984 to Dec 1990 Retrospective study 60 ≤ 20 days, > 20 days 9.17 (1.49-56.3), 0.01 CA125 half-life provides an independent prognostic factor for survival in stage III-IV patients early in the course of therapy Stage, histology, grade, tumor rest
Hogberg T, 1990, Sweden [67] 1984-1987 Prospective study 72 ≤ 8 days, 8 - ≤ 12 days, 12 < - ≤ 16 days, > 16 days NA, 0.003 The patients with a short serum CA125 half-life had a significantly better probability of survival Age, histology
FIGO stage, residual tumor, grade
Hunter VJ, 1990, Durham [68] March 1984 to Jan 1989 Prospective study 54 ≤ 20 days, > 20 days NA, < 0.015 Overall survival was significantly greater in patients with a CA125 half life ≤ 20 days NA
Hawkins RE, 1989, London [69] NA Prospective study 29 < 20 days, 20-40 days, > 40 days 3.7 (0.7-20.1), 0.001;
27.8 (4.0-193), 0.001
CA125 half life was independent prognostic indicator for survival Residual tumor, stage, ascites
van der Burg ME, 1988, Netherlands [44] Sept 1979 to Dec 1983 Consecutive case series 85 < 20 days, ≥ 20 days NA The half-life of CA125 appeared to be significantly and independently correlated with progression rate and progression-free survival FIGO stage, histology, histological grade, postoperative tumor size